At early clinical stages of transgenic AD mice models, astrocytes showed atrophy—reduced volume, surface area, and morphological complexity—and reduced GFAP expression, while disease progression corresponded to increased GFAP expression22. This evidence concerns the gene GFAP and Alzheimer disease.